PIN1 and acute promyelocytic leukemia: Unlike PiB and juglone, ATRA treatment in cells leads to the degradation of Pin1 and exhibits anti-cancer properties against TNBC and acute promyelocytic leukemia (APL); however, in TNBC mouse models, ATRA treatment showed only moderate antitumor activity (Wei et al., 2015).